Study guide

6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

Key Takeaways Explain This Topic AI

Hyperacute rejection occurs within minutes from preformed antibodies, acute cellular rejection over weeks is T-cell mediated, and chronic rejection over months to years produces vascular intimal fibrosis.

Graft-versus-host disease occurs when immunocompetent donor T cells attack host tissues, classically skin (including palms and soles), liver and gut; irradiating blood products prevents transfusion-associated GVHD.

Tumors evade immunity by losing MHC class I, expressing PD-L1 and recruiting regulatory T cells; checkpoint inhibitors block CTLA-4 or PD-1/PD-L1 and can cause immune-related arthritis, dermatitis and colitis.

ELISA, agglutination, immunofluorescence, Western blot and flow cytometry all rely on specific antigen-antibody binding; a direct Coombs test detects antibody already on red cells, while an indirect Coombs test detects antibody free in serum.

Positive predictive value depends on prevalence: a test with 90% sensitivity and 95% specificity has a PPV of about 67% when disease prevalence is 10%.

Last updated: October 2026

6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

Sections 6.3 and 6.4 covered innate and adaptive immunity, hypersensitivity and immunodeficiency. The Part I outline also lists transplantation and tumor immunology and immunodiagnostic methods . These topics show up in podiatry through transplant recipients with foot infections and skin cancers, allograft use in reconstruction, checkpoint-inhibitor side effects and serologic test interpretation.

Graft Terminology

  • Graft Donor-recipient relationship Example in foot and ankle care
  • Autograft Same person Calcaneal or proximal tibial bone graft; split-thickness skin graft
  • Isograft (syngeneic) Genetically identical twin Rare

Allograft Same species, different person Freeze-dried bone allograft, fresh osteochondral talar allograft, acellular dermal matrix

Xenograft Different species Porcine or bovine collagen matrices

Recipients recognize donor HLA (MHC) molecules in two ways. In direct allorecognition , recipient T cells react to intact donor MHC on donor antigen-presenting cells. In indirect allorecognition , recipient antigen-presenting cells process donor MHC into peptides and present them on recipient MHC. Freezing or freeze-drying bone allograft kills donor cells and lowers immunogenicity, while fresh osteochondral allografts preserve chondrocyte viability but carry more donor antigen. All tissue allografts are screened to reduce the risk of transmitting disease.

Patterns of Rejection

Type Timing Mechanism Pathology

Hyperacute Minutes to hours Preformed antibodies (ABO or HLA) bind graft endothelium and activate complement (Type II) Immediate thrombosis and ischemic necrosis; prevented by ABO matching and crossmatch

Acute cellular Weeks to months CD8+ and CD4+ T cells against donor MHC (Type IV) Lymphocytic infiltrates; usually reversible with intensified immunosuppression

Acute antibody-mediated Days to months Donor-specific antibodies Capillary inflammation with C4d deposition

Chronic Months to years Mixed cellular and humoral injury Intimal fibrosis of graft arteries , interstitial fibrosis, obliterative bronchiolitis in lung grafts

Graft-versus-Host Disease (GVHD)

In GVHD the graft attacks the host. Immunocompetent donor T cells in a hematopoietic stem cell transplant (or, rarely, in a non-irradiated blood product given to an immunodeficient patient) recognize host tissues as foreign. Acute GVHD targets the skin (a maculopapular rash that often begins on the palms and soles ), the liver (cholestatic jaundice) and the gut (diarrhea). Chronic GVHD produces sclerodermatous skin and joint contractures. Irradiation of blood products prevents transfusion-associated GVHD.

Consequences of Chronic Immunosuppression

Transplant recipients take calcineurin inhibitors, antimetabolites, mTOR inhibitors and corticosteroids (pharmacology in 12.4). Clinical consequences in the lower extremity include:

  • Atypical and opportunistic infections (fungal, nocardial, mycobacterial and viral)
  • Blunted inflammatory signs, so infection can present with little redness or fever
  • Cutaneous squamous cell carcinoma , which is many times more frequent than in the general population
  • Delayed wound healing, particularly with mTOR inhibitors and high-dose corticosteroids
  • Tumor Immunology

Tumor antigens include:

Tumor-specific neoantigens from mutated proteins, such as mutant RAS or BRAF peptides

Tumor-associated antigens that are overexpressed or re-expressed normal proteins, such as oncofetal CEA and alpha-fetoprotein

Viral antigens in virus-driven cancers: HPV E6/E7, EBV and HHV-8 in Kaposi sarcoma

Immune surveillance relies on CD8+ cytotoxic T cells, which recognize tumor peptides on MHC class I, and on natural killer (NK) cells , which kill cells that have lost MHC class I ("missing self").

Immune evasion mechanisms include:

  • Downregulating MHC class I
  • Expressing PD-L1 , which engages PD-1 on T cells and induces exhaustion
  • Recruiting regulatory T cells and secreting TGF-beta and IL-10
  • Selecting antigen-loss variants
  • Checkpoint Inhibitors and Immune-Related Adverse Events
  • Target Drugs Notes
  • CTLA-4 Ipilimumab Removes a brake on T-cell priming in lymph nodes
  • PD-1 Nivolumab, pembrolizumab Restores effector T-cell activity in the tumor; widely used in advanced melanoma
  • PD-L1 Atezolizumab, durvalumab Blocks the ligand on tumor cells

Releasing these brakes can cause immune-related adverse events : dermatitis and vitiligo-like depigmentation, colitis, hepatitis, hypophysitis, thyroiditis, pneumonitis, and inflammatory arthritis that may begin in the feet . CAR-T cell therapy (for example, anti-CD19 for B-cell malignancies) can cause cytokine release syndrome.

Pathology markers. Immunohistochemical stains help confirm tumor type, for example S-100, SOX10, HMB-45 and Melan-A (MART-1) for melanoma. Serum markers such as PSA, CA-125, CEA, AFP and LDH are used mainly to monitor known cancers, not to screen the general population.

Immunodiagnostic Methods

Method Principle Common uses

Agglutination Antibody cross-links particulate antigens (cells or latex beads) into visible clumps Blood typing; latex rheumatoid factor; Coombs tests

Precipitation and immunodiffusion Soluble antigen-antibody lattices form visible lines Older fungal serologies; serum protein immunofixation

ELISA Enzyme-linked antibody converts a substrate into a color change proportional to the bound analyte HIV and hepatitis screening; anti-CCP; many serologies

  • Lateral flow immunoassay ELISA principle on a test strip Rapid antigen tests
  • Western blot Proteins separated by size, then probed with antibody Confirmation in selected infections

Immunofluorescence Fluorescent antibody binds tissue antigen (direct) or detects patient antibody on a substrate (indirect) Direct immunofluorescence of skin biopsies (pemphigus, pemphigoid); ANA patterns

Flow cytometry Fluorescent antibodies label cell-surface markers on single cells in suspension CD4 counts in HIV; leukemia immunophenotyping; DHR test for CGD

  • Complement assays C3, C4 and CH50 levels Consumption in SLE and immune-complex disease
  • IGRA Interferon-gamma released by T cells after TB antigen exposure Latent TB screening before biologics

Coombs testing. The direct antiglobulin (direct Coombs) test adds anti-human globulin to the patient's washed red cells to detect antibody or complement already bound to them (autoimmune hemolytic anemia, hemolytic transfusion reactions). The indirect Coombs test detects free antibody in serum (antibody screening before transfusion and in pregnancy).

Interpreting serology. IgM suggests recent infection and IgG suggests past infection or immunity. A fourfold rise in titer between acute and convalescent samples supports acute infection.

Worked Example: Predictive Values

A serologic test has 90% sensitivity and 95% specificity . In 1,000 patients with 10% prevalence (100 diseased):

  • True positives = 90 and false negatives = 10
  • Of 900 non-diseased, false positives = 45 and true negatives = 855
  • PPV = 90 / (90 + 45) = 66.7%
  • NPV = 855 / (855 + 10) = 98.8%

At 1% prevalence the PPV of the same test falls to about 15%. Predictive values shift with prevalence; sensitivity and specificity do not.